Keybanc Maintains Overweight on Exagen, Lowers Price Target to $17
Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and lowers the price target from $20 to $17.
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell
• Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
Exagen Expands In-Network Access With Evolutions Healthcare Systems
Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access
Exagen: Q4 Earnings Insights
Exagen (NASDAQ:XGN) reported its Q4 earnings results on Tuesday, March 22, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
A Preview Of Exagen’s Earnings
Exagen (NASDAQ:XGN) is set to give its latest quarterly earnings report on Tuesday, 2022-03-22. Here's what investors need to know before the announcement.
Analysts estimate that Exagen will report an earnings per share (EPS) of $-0.50.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows.
Exagen and Queen Mary University of London Announced Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a research collaboration and exclusive license agreement.
Keybanc Maintains Overweight on Exagen, Lowers Price Target to $30
Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and lowers the price target from $33 to $30.
Exagen Q3 EPS $(0.42) Beats $(0.46) Estimate, Sales $12.25M Beat $12.13M Estimate; Reaffirms FY21 Sales Guidance $47M-$49M
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.46) by 8.7 percent. This is a 23.53 percent decrease over losses of $(0.34) per share from the same